Bridging the gap between scientific discovery and investment-ready innovation for rare disease breakthroughs.

ERDERA Technology Accelerator

The ERDERA Technology Accelerator advances the enabling technologies that make rare-disease therapies possible. We bring public and private partners together to mature, validate, and streamline advanced therapy platforms so promising discoveries can move faster, safer, and more efficiently toward the clinic.

By strengthening shared technological toolboxes for the rare disease community, we help reduce development risk and accelerate translation across multiple indications.

You are a technology developer…

…working on enabling technologies for rare-disease therapies within academia, a research infrastructure, an SME, or industry.

…developing platforms such as viral or non-viral delivery systems, gene-editing tools, therapeutic RNAs, or analytical and manufacturing solutions.

…looking to improve robustness, scalability, comparability, or clinical relevance of your technology through collaboration and real-world feedback.

If this sounds like you, the Technology Accelerator can help.

The Technology Accelerator supports partners by:

Advancing enabling ATMP technologies, including:

Adeno-associated Virus (AAVs)

Messenger RNA (mRNA)

Lipid Nanoparticles, Extracellular Vesicles, Biohybrids

Gene Editing Tools

Addressing key technical bottlenecks across:

Delivery efficiency and tissue targeting

Manufacturing and scale-up

Analytical characterisation and quality control

Evaluation of therapy response, safety, and immunogenicity

Facilitating pre-competitive collaboration between public and private stakeholders to strengthen shared technology platforms.

Aligning technology development with translational and clinical needs in rare diseases.

Why it matters

Robust, well-validated enabling technologies are essential for translating rare-disease discoveries into viable therapies. By strengthening these foundations, the Technology Accelerator supports not just individual projects but the entire rare-disease innovation ecosystem.

Latest relevant publications

Standardized transcriptome analysis improves rare disease diagnosis in the pan-European Solve-RD consortium

14 February 2026

Long-read genome sequencing (lrGS) has the potential to consolidate current standard-of-care (SoC) diagnostics into a single assay, but its accuracy and clinical utility in routine practice have not been established at large scale.

Clinical long-read genome sequencing for rare disease diagnostics

18 January 2026

Tailored antisense oligonucleotides for ultrarare CNS diseases: An experience-based best practice framework for individual patient evaluation

23 December 2025

Outside traditional drug development pathways, clinicians and scientists face the challenge of systematically evaluating whether individual patients with severe ultrarare diseases might be eligible for and potentially benefit from individualized mutation-specific RNA therapies.

PROTRIDER: protein abundance outlier detection from mass spectrometry-based proteomics data with a conditional autoencoder

20 November 2025

PROTRIDER is a method for detecting aberrant protein expression from mass spectrometry data that outperforms existing approaches and identifies enrichments of pathogenic variants, supporting its application in rare disease diagnostics and cancer proteomics.

Accelerating Innovation Through Coordinated Research Platforms: The ERDERA Approach

10 November 2025

On November 12 at 11:00am (GMT+3) , IBG RareBoost will host Dr. Başak Uysal from the ERDERA Coordination Team. She will deliver a presentation titled “Accelerating Innovation Through Coordinated Research Platforms: The ERDERA Approach.”